TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 12.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,320 shares of the biopharmaceutical company’s stock after acquiring an additional 8,249 shares during the quarter. Wellington Management Group LLP’s holdings in TG Therapeutics were worth $1,715,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. State Street Corp lifted its stake in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the last quarter. Marshall Wace LLP bought a new position in shares of TG Therapeutics in the 2nd quarter worth about $36,501,000. Hood River Capital Management LLC boosted its holdings in shares of TG Therapeutics by 6.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock valued at $27,982,000 after buying an additional 98,892 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of TG Therapeutics by 0.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock valued at $27,708,000 after buying an additional 7,939 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently commented on TGTX. HC Wainwright upped their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 14th. TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. Finally, The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Price Performance

Shares of TGTX opened at $31.07 on Thursday. TG Therapeutics, Inc. has a one year low of $12.84 and a one year high of $36.84. The stock’s fifty day moving average is $29.24 and its 200-day moving average is $23.74. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market capitalization of $4.84 billion, a price-to-earnings ratio of -310.67 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm’s quarterly revenue was down 49.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.73 EPS. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.